KMTS — Kestra Medical Technologies, Ltd. stock price, charts and financials

QT50Kestra Medical Technologies, Ltd.

Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
24.43
+0.08+0.33%
OverviewShort InterestFilings
KMTSQT50Kestra Medical Technologies, Ltd.·NASDAQ
24.43+0.33%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AZTA-1.16%$33.24BLFS-0.43%$36.69LMAT-0.76%$78.87XRAY+1.71%$9.54STAA-1.98%$20.82NNNN-6.25%$5.25ATRC-1.73%$58.10ANGO+0.46%$15.44
Snapshot
Index-P/E-EPS (ttm)-2.42Insider Own2.19%Shs Outstand58.60MPerf Week6.91%
Market Cap1.43BForward P/E-EPS next Y-2.11Insider Trans-22.59%Shs Float33.06MPerf Month-12.47%
Enterprise Value1.28BPEG-EPS next Q-Inst Own-Short Float8.99%Perf Quarter22.58%
Income-132.00MP/S14.91EPS this Y-1.35%Inst Trans-Short Ratio8.03Perf Half Y24.90%
Sales96.00MP/B5.51EPS next Y13.82%ROA-36.72%Short Interest2.97MPerf YTD-7.88%
Book/sh4.44P/C7.30EPS next 5Y-ROE-58.76%52W High30.00 -18.57%Perf Year2.95%
Cash/sh3.34P/FCF-EPS past 3/5Y-ROIC-43.73%52W Low17.34 40.89%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y128.15% -Gross Margin51.37%Volatility7.61% 5.32%Perf 5Y-
Dividend TTM-EV/Sales13.36EPS Y/Y TTM52.83%Oper. Margin-141.64%ATR (14)1.46Perf 10Y-
Dividend Ex-Date-Quick Ratio4.28Sales Y/Y TTM60.00%Profit Margin-138.36%RSI (14)45.95Recom2.25
Dividend Gr. 3/5Y-Current Ratio4.41EPS Q/Q66.06%SMA20-3.12%Beta1.60Target Price30.67
Payout-0.25%Debt/Eq0.18Sales Q/Q70.59%SMA50-2.61%Rel Volume3.12Prev Close24.35
Employees443LT Debt/Eq0.18EarningsDec 10SMA2003.97%Avg Volume400.22KPrice24.43
IPO DateMar 06, 2025Option/ShortYes / YesEPS/Sales Surpr.-21.78% 8.15%Net Debt/EBITDA0.40Volume1,249,221Change0.33%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-15-26ReiteratedRBC Capital$30
Jul-15-26ReiteratedWolfe Research$30
Jul-15-26ReiteratedBTIGBuy$32
Jan-16-26ReiteratedGoldman SachsNeutral$27 → $24
Jan-09-26ReiteratedGoldman SachsNeutral$25 → $27
Dec-12-25ReiteratedStifel Nicolaus$28 → $30
Dec-12-25ReiteratedWells FargoOverweight$28
Dec-12-25ReiteratedPiper SandlerOverweight$30
Latest News· Times ET
Sep-17-26
Sep-17-2605:14PM
Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?Yahoo
Sep-16-26
Sep-16-2603:45AM
Kestra Medical: Strong Scaling Story, But Profitability Still On The Horizonseekingalpha.com
Sep-15-26
Sep-15-2609:21PM
Kestra Medical Technologies (NASDAQ:KMTS) Shares Gap Down After Earnings Missdefenseworld.net
04:02AM
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Sep-14-26
Sep-14-2610:11PM
Kestra Medical Technologies, Ltd. (KMTS) Q1 2027 Earnings Call Transcriptseekingalpha.com
02:26PM
Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimateszacks.com
02:04PM
Kestra Medical Technologies Q1 Earnings Call Highlightsmarketbeat.com
12:01PM
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Resultsglobenewswire.com
Sep-11-26
Sep-11-2602:01AM
Kestra Likely To Report Q1 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga
Sep-10-26
Sep-10-2602:00AM
Kestra Names Daniel Finney Vice President of Research & Developmentglobenewswire.com
Sep-07-26
Sep-07-2607:00AM
Analysts Estimate Kestra Medical Technologies, Ltd. (KMTS) to Report a Decline in Earnings: What to Look Out forzacks.com
Sep-02-26
Sep-02-2602:10AM
BTIG Reiterates Buy on Kestra Medical Techs, Maintains $32 Price TargetBenzinga
Aug-31-26
Aug-31-2612:01PM
Kestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14globenewswire.com
Aug-26-26
Aug-26-2602:00AM
Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experienceglobenewswire.com
Aug-25-26
Aug-25-2601:06PM
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga
Company

Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
4/30/2026
FY 2025
4/30/2025
FY 2024
4/30/2024
FY 2023
4/30/2023
Total Revenue969560——
Cost of Goods Sold Incl. D&A474636——
Gross Profit494924——
Selling, General and Administrative Excl. Other164164115——
Research and Development201916——
Other Operating Expense010——
Operating Income-135-135-106——
Interest Expense888——
Unusual Expense
—————
Non-Operating Income (Expense)12110——
Net Income Before Taxes-132-131-114——
Income Taxes
000——
Consolidated Net Income-132-132-114——
Net Income From Continuing Operations-132-132-114——
Net Income-132-132-114——
EPS (Recurring)-2.42-2.43-5.13——
EPS (Basic, Before Extraordinaries)-2.42-2.43-5.13——
EPS (Diluted)-2.42-2.43-5.13——
EBITDA-130-150-98——
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio14.7612.6520.05——
Gross Margin51.0451.5840.00——
Operating Margin-140.63-142.11-176.67——
Net Margin-137.50-138.95-190.00——
Shares Outstanding585850——
Market Capitalization1,4171,2021,203——
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$30.43$25.92$21.41$16.89$12.38● Close Price0.00M0.94M1.88M2.82M3.76MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Ladone Mary KayDirectorSep 08 '26Sale25.203,90898,46437,507Sep 10
Reilly Kevin CDirectorSep 08 '26Sale25.132,93273,6775,368Sep 10
Hanley ConorDirectorSep 08 '26Sale25.255,694143,7796,272Sep 10
Schwartz Jeffrey Lawrencedirector, 10 percent owner:Sep 08 '26Sale25.183,89097,9427,019Sep 10
Webster Brian DanielSee RemarksAug 17 '26Sale27.4815,000412,181460,215Aug 18
Mahboob VaseemChief Financial OfficerAug 07 '26Sale25.8826,287680,38360,609Aug 11
Webster Brian DanielSee RemarksAug 04 '26Sale24.5251,9001,272,588475,215Aug 06
Ford Alfred J JrChief Commercial OfficerAug 04 '26Sale24.096,275151,14199,564Aug 06
Mahboob VaseemChief Financial OfficerAug 04 '26Sale24.686,995172,63586,896Aug 06
Umberger Traci SSee RemarksAug 04 '26Sale24.043,58086,073195,825Aug 06
Ford Alfred J JrChief Commercial OfficerAug 03 '26Sale23.9013,015311,118105,839Aug 03
Moran Timothy P.Chief Business OfficerAug 03 '26Sale23.762,38056,55166,345Aug 03
Umberger Traci SSee RemarksAug 03 '26Sale23.867,590181,062199,405Aug 03
Mahboob VaseemChief Financial OfficerAug 03 '26Sale23.805,391128,31293,891Aug 03
Webster Brian DanielSee RemarksAug 03 '26Sale23.9213,017311,424527,115Aug 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.